64190-52-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Hydroxy-1-methyl-ethyl)-7a-methyl-octahydro-inden-4-ol is used as a key intermediate for the preparation of Vitamin D metabolites and analogs. Its unique structure allows it to play a crucial role in the synthesis of these biologically active compounds, which are essential for maintaining proper health and functioning of the human body.
Used in Vitamin D Research and Development:
In the field of research and development, 1-(2-Hydroxy-1-methyl-ethyl)-7a-methyl-octahydro-inden-4-ol serves as a valuable intermediate for the creation of new Vitamin D analogs. These analogs can be designed to have improved properties, such as enhanced bioavailability, increased potency, or reduced side effects, making them more effective in treating various health conditions related to Vitamin D deficiency or imbalance.
Overall, 1-(2-Hydroxy-1-methyl-ethyl)-7a-methyl-octahydro-inden-4-ol is a versatile and important compound in the pharmaceutical industry, particularly in the development and production of Vitamin D-related products. Its unique structure and properties make it a valuable asset in the ongoing quest to improve human health and well-being.

InChI:InChI=1/C13H24O2/c1-9(8-14)10-5-6-11-12(15)4-3-7-13(10,11)2/h9-12,14-15H,3-8H2,1-2H3/t9-,10?,11?,12+,13-/m1/s1

Upstream product

• 50-14-6 Calciferol 
• 50-14-6 vitamin D₂ 
• 104846-62-0 3(S)-tert-butyldimethylsilyloxy-9,10-secoergosta-5,7(E),10⁽¹⁹⁾,22(E)-tetraene 

Downstream Products

• 189102-18-9 des-A,B-8β-[(triethylsilyl)oxy]-22-(p-toluenesulfonyloxy)-23,24-dinorcholane 
• 100928-03-8 (S)-2-((1R,3aR,4S,7aR)-4-(tert-butyldimethylsilyloxy)-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol 
• 725229-55-0 (1R,3aR,7aR)-7a-Methyl-1-[(R)-1-methyl-2-(1-phenyl-1H-[1,2,3]triazol-4-yl)-ethyl]-octahydro-inden-4-one 
• 725229-54-9 (1R,3aR,4S,7aR)-7a-Methyl-1-[(R)-1-methyl-2-(1-phenyl-1H-[1,2,3]triazol-4-yl)-ethyl]-octahydro-inden-4-ol 
• 725229-53-8 4-[(R)-2-((1R,3aR,4S,7aR)-7a-Methyl-4-triethylsilanyloxy-octahydro-inden-1-yl)-propyl]-1-phenyl-1H-[1,2,3]triazole 
• 725227-35-0 2-[1-((S)-2-{(1R,3aS,7aR)-4-[2-[(S)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propyl)-1H-[1,2,3]triazol-4-yl]-propan-2-ol 
• 725227-40-7 1-((S)-2-{(1R,3aS,7aR)-4-[2-[(S)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 725229-60-7 4-((R)-2-{(1R,3aS,7aR)-4-[2-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propyl)-1-phenyl-1H-[1,2,3]triazole 
• 725229-62-9 1,4-bis-[2-(4-{2-[3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-propyl]-1H-[1,2,3]triazole 
• 248257-32-1 Toluene-4-sulfonic acid (R)-2-((1R,3aR,4S,7aR)-4-hydroxy-7a-methyl-octahydro-inden-1-yl)-propyl ester 
• 171011-50-0 (1R,3aR,4S,7aR)-1-{(R)-2-[3-(1-Hydroxy-1-methyl-ethyl)-phenylsulfanyl]-1-methyl-ethyl}-7a-methyl-octahydro-inden-4-ol 
• 1025981-64-9 (1R,3aR,7aR)-1-{(R)-2-[3-(1-Hydroxy-1-methyl-ethyl)-phenylsulfanyl]-1-methyl-ethyl}-7a-methyl-octahydro-inden-4-one 
• 171230-80-1 (1R,3aR,7aR)-7a-Methyl-1-{(R)-1-methyl-2-[3-(1-methyl-1-trimethylsilanyloxy-ethyl)-phenylsulfanyl]-ethyl}-octahydro-inden-4-one 
• 183506-75-4 (R)-2-((1R,3aR,4S,7aR)-4-(tert-butyldimethylsilyloxy)-7a-methyloctahyrdo-1H-inden-1-yl)propyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

NOVEL METHOD

There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound.

SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL

The invention provides a method of producing 20-methyl vitamin D3 compounds of formula (I). The method includes hydroxylation, carbonyl reduction, fluoride substitution, epoxide deoxygenation, and Wittig-type couplings.

SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL

The invention provides a method of producing 20-methyl vitamin D3 compounds of formula (I). The method includes allylic and olefin oxidation, decarbonylation, carbonyl reduction, fluoride substitution, epoxide deoxygenation, and Wittig-type couplings.